Barbara Ryan

Articles

Reading the Tea Leaves for Biotech As 2024 Approaches

Could the sector please get a little ‘rate’ relief?

Are We Close to a Peak in Interest Rates?

When you know it is coming—but it takes forever to get there.

No Rate Relief in Sight for Biotech

Strong economic data in other sectors mean rising ‘real’ rates.

More Evidence is Pointing to Potential Swing for Biotech

Could the sector be nearing a turning point in performance?

Shifting Macro Trends Offer Hope for Biotech Performance Boost

But will Washington’s dealmaking stance upend the momentum?

Could a Rates Pivot By Fed Change Biotech’s Fate?

Such a scenario is one possibility as the bear market languishes on.